Cancer Forums and News by PhD's


News | Forums Register

Go Back   Cancer Forums and News by PhD's > Cancer Forums and News

Cancer News

Breast
Colon
Kidney
Leukemia
Liver
Lung
Melanoma
Mesothelioma
Myeloma
Neck
Pancreatic
Prostate


Cancer Review

Breast
Colon
Kidney
Leukemia
Liver
Lung
Melanoma
Mesothelioma
Myeloma
Pancreatic
Prostate


Recent Forum Topics

 
cll
Novel Experimental Agent Is Highly Active In CLL Patients, Interim Study Shows
By Dross at 2011-06-06 22:49
 

 COLUMBUS, Ohio – An interim analysis of a phase II clinical trial indicates that a novel experimental agent for chronic lymphocytic leukemiaterm (CLL) is highly active and well tolerated both in patients who are undergoing treatment for the first time and those who have relapsed and are resistant to other therapy. 

read more | 19072 reads

MMayo Clinic Researchers Find Predictive Tests and Early Treatment Delay Progression of Blood Cell Cancer
By Dross at 2008-11-08 02:46
 

Mayo Clinic researchers say they have moved closer to their goal of providing personalized care for a common blood cell cancer. They have found that the use of predictive biomarkers along with two targeted treatments significantly delays the need for conventional chemotherapyterm in patients with early-stage, but high-risk, chronic lymphoid leukemiaterm (CLL).

Their study, published Oct. 15 in the journal Cancer, found that in a small group of patients the use of the new tools delayed the need for standard chemotherapy treatment to about four years after cancer diagnosis. Typically, people with this kind of high-risk CLL require chemotherapy at about two years after diagnosis.

read more | 1279 reads

Clinical study shows biological and clinical activity in relapsed leukemia patients
By Dross at 2008-06-05 21:29
 

LUGANO, SWITZERLAND, June 4, 2008 – Finbarr Cotter, M.D., Ph.D., Professor of the Institute of Cell and Molecular Science at Barts and The London School of Medicine, today presented in an oral session "Clinical Caspase Activation in CLL by GCS-100: a Phase 2 Study" at the 10th International Conference on Malignant Lymphomaterm (10-ICML). The promising interim results from this ongoing clinical trial indicate that single-agent GCS-100 induces apoptosis (programmed cell death) in patients' CLL cells, reduces leukocyte count in some patients and is generally well tolerated. GCS-100 targets galectin-3, a protein over-expressed in cancer cells that promotes their survival, proliferation and metastasistermterm.

read more | 1123 reads

Gene therapy protocol at UCSD activates immune system in patients with leukemia
By Dross at 2008-02-13 01:36
 

A research team at the Moores Cancer Center at University of California, San Diego (UCSD) reports that patients with chronic lymphocytic leukemiaterm (CLL) who were treated with a gene therapy protocol began making antibodies that reacted against their own leukemia cells. The study will be published on line the week of February 11-15 in the online edition of the Proceedings of the National Academy of Science.

Researchers led by Thomas J. Kipps, M.D., Ph.D., inserted a gene with the potential to activate an immune response – a gene therapy protocol developed at UCSD – into six patients with CLL, the most common form of adult leukemia. Several of the patients started making antibodies that reacted against their own leukemia cells. When tested in the lab, the antibodies also reacted with the leukemia cells of other patients with the disease.

read more | 1836 reads

Massey researchers induce cell death in leukemia
By Dross at 2007-04-16 22:35
 

Researchers from the Virginia Commonwealth University Massey Cancer Center today presented preclinical research at the American Association of Cancer Research's annual meeting suggesting the potential of a new combination treatment for chronic lymphocytic leukemiaterm (CLL).

In this study, led by Steven Grant, M.D., Massey's associate director of translational research, interactions between bortezomib and romidepsin (Gloucester Pharmaceuticals) and bortezomib with belinostat (aka PXD101 from CuraGen Corporation and TopoTarget A/S), were examined in human CLL cells isolated from five patients. Bortezomib dramatically potentiated the lethality of both agents in cells from four of five patients, while exerting additive effects in cells from one patient. Notably, pronounced lethality was observed following treatment of cells with very low concentrations of the agents.

read more | 1 comment | 1211 reads

Genta Cites Publication of Study Showing Improved Outcomes in CLL Patients Treated With Genasense(R) Plus Chemotherapy
By Dross at 2007-02-16 03:11
 

BERKELEY HEIGHTS, N.J., Feb. 14 -- Genta Incorporated (NASDAQ:GNTA) today announced the publication of findings from a Phase 3 trial of the Company's lead anticancer drug, Genasense(R) (oblimersen sodium) Injection, when used in combination with chemotherapyterm for treatment of patients with relapsed or refractory chronic lymphocytic leukemiaterm (CLL). The findings were published on-line this week in the Journal of Clinical Oncology, ahead of its tentatively scheduled print publication date of March 20, 2007. Conducted at 100 centers in the U.S., Europe, Canada, Australia and South America, patients with relapsed or refractory CLL received fludarabine plus cyclophosphamide (Flu/Cy) chemotherapy with or without Genasense. This trial -- the first randomized study ever conducted in this population -- achieved its primary endpoint, which was a statistically significant increase in the proportion of patients who achieved a complete or nodular partial response (CR/nPR) (17% vs. 7%; P=0.025). Patients who achieved CR/nPR experienced the disappearance of all predefined CLL symptoms, including fever, night sweats, fatigue, abdominal discomfort due to an enlarged spleen, and impaired mobility due to swollen lymph nodes. The key secondary endpoint -- duration of CR/nPR -- was also significantly longer for patients treated with Genasense (median = not reached but will exceed 36 months in the Genasense group vs. 22 months for patients treated with chemotherapy alone). Among patients who achieved a CR/nPR with Genasense, 70 percent were alive at three years versus 38 percent for the control arm. Among patients who achieved a partial response, 45 percent who received Genasense were alive at three years compared to 33 percent for the control arm. The lead and senior authors of the article are, respectively, Dr. Susan O'Brien, Professor of Medicine, Department of Leukemia, M.D. Anderson Cancer Center, and Dr. Kanti R. Rai, Chief, Hematology and Oncology, North Shore/Long Island Jewish Medical Center, and Professor of Medicine, Albert Einstein College of Medicine. An abstract of this article that addresses safety and efficacy in the trial can be accessed at:

read more | 1605 reads

First antisense drug provides benefit to subset of chronic lymphocytic leukemia patients
By Dross at 2007-02-15 06:24
 

    The first "antisense" drug to be tested in chronic lymphocytic leukemiaterm (CLL) shows benefit in a phase III clinical trial for a specific subset of patients - those who are still sensitive to a chemotherapyterm drug often used to treat this cancer. Researchers at The University of Texas M. D. Anderson Cancer Center, reporting in the early on-line edition of the March 20 Journal of Clinical Oncology, found that the agent, oblimersen (trade name: Genasense) produced a four-fold increase in "CP/nPR," a clinical response defined by no definitive evidence of disease, in patients who were sensitive to the chemotherapy drug fludarabine, compared to patients who no longer responded to fludarabine. "The results make sense because oblimersen is designed to work alongside chemotherapy," says the study's lead author, Susan O'Brien, M.D., professor in the Department of Leukemia. "We found in this study that oblimersen enhances sensitivity to chemotherapy, and so we think it deserves further study in a population of CLL patients who are sensitive to chemotherapy agents," she says. CLL, a cancer of the blood and bone marrow, is the second most common type of leukemia in adults.

read more | 1428 reads

In-tandem insight from basic science combined with clinical research: CD38 as both marker and key component of the pathogenetic
|
By admin at 2006-12-08 23:08
 
<p>[via <a href="http://www.bloodjournal.org/cgi/content/full/108/4/1135">In-tandem insight from basic science combined with clinical research: CD38 as both marker and key component of the pathogenetic network underlying chronic lymphocytic leukemia -- Deaglio et al. 108 (4): 1135 -- Blood</a>]:</p><p>In-tandem insight from basic science combined with clinical research: CD38 as both marker and key component of the pathogenetic network underlying <strong>chronic lymphocytic leukemia</strong> Silvia Deaglio, Tiziana Vaisitti, Semra Aydin, Enza Ferrero, and Fabio Malavasi From the Lymphocyte Signaling Unit, Laboratory of Immunogenetics, Department of Genetics, Biology and Biochemistry &amp; CeRMS, University of Torino Medical School, Torino, Italy. Abstract The absence of mutations in the IgV genes, together with the presence of ZAP-70 and CD38, are the most reliable negative prognostic markers for chronic lymphocytic leukemia (CLL) patients. Several lines of evidence indicate that CD38 may be not only a diagnostic marker but also a key element in the pathogenetic network in CLL. First, CD38 is a receptor that induces proliferation and increases survival of CLL cells. Second, CD38 signals start upon interaction with the CD31 ligand expressed by stromal and nurse-like cells. Third, CD38/CD31 contacts up-regulate CD100, a semaphorin involved in sustaining CLL growth. Fourth, evidence that nurselike cells express high levels of CD31 and plexin-B1, the high-affinity ligand for CD100, offers indirect confirmation for this model of receptor cross-talk. Elements of variation in the clinical course of CD38 CLL patients include (1) potential intersection with ZAP-70, a kinase involved in the CD38 signaling pathway in T and natural killer (NK) cells, and (2) the effects of genetic polymorphisms of the receptors involved, at least of CD38 and CD31. Consequently, CD38 together with ZAP-70 appear to be the key elements of a coreceptor pathway that may sustain the signals mediated by the B-cell receptor and potentially by chemokines and their receptors. This would result in acquisition of increased survival potential, providing clues to the poorer prognosis of CD38 patients.</p>
read more | 1269 reads

Syndicate content
 
Search

sponsored links




Donate


Newsletter



Subscribe to our newsletter to receive info on our site or upcoming clinical trials
Email

Confirm your email address

HTML format
State

Please select the newsletters you want to sign up to:

  • Cancerfocus
    Receive updates from Cancerfocus.
  • Breast
  • Colon
  • Kidney
  • Leukemia
  • Liver
  • Lung
  • Melanoma
  • Mesothelioma
  • Myeloma
  • Neck
  • Pancreatic
  • Prostate




Syndicate
Syndicate content


All times are GMT -5. The time now is 05:24 PM.